Plus Therapeutics, Inc. (PSTV) – What Are Analysts Thinking About This Stock?

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have received an average rating of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $51.75.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new stake in Plus Therapeutics stock. Citadel Advisors LLC purchased a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 25,597 shares of the company’s stock, valued at approximately $112,000. Citadel Advisors LLC owned 0.37% of Plus Therapeutics as of its most recent SEC filing. Institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Trading Up 1.2%

Shares of PSTV opened at $1.75 on Friday. The company has a market cap of $12.05 million, a price-to-earnings ratio of -0.76 and a beta of 1.40. The business’s fifty day simple moving average is $2.29 and its two-hundred day simple moving average is $4.00. Plus Therapeutics has a 12 month low of $2.90 and a 12 month high of $23.42.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.43). The business had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.11 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%. As a group, research analysts forecast that Plus Therapeutics will post -3.76 EPS for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s approach combines radioactive isotopes with nanoparticle-based drug-delivery technology designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nano liposomes, also known as 186RNL. The treatment is being evaluated for recurrent glioblastoma and leptomeningeal metastases, cancers affecting the brain and spinal cord.